Lazard Asset Management LLC Sells 17,955 Shares of Vaxcyte, Inc. $PCVX

Posted by Geri Gentry on Aug 2nd, 2026

Lazard Asset Management LLC cut its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 27.6% during the 1st quarter, Holdings Channel.com reports. The firm owned 47,023 shares of the company’s stock after selling 17,955 shares during the quarter. Lazard Asset Management LLC’s holdings in Vaxcyte were worth $2,733,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Inceptionr LLC purchased a new stake in Vaxcyte in the first quarter worth about $334,000. Sei Investments Co. lifted its position in shares of Vaxcyte by 8.4% during the 1st quarter. Sei Investments Co. now owns 33,545 shares of the company’s stock valued at $1,949,000 after buying an additional 2,605 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of Vaxcyte by 23.1% during the 1st quarter. Cetera Investment Advisers now owns 9,595 shares of the company’s stock valued at $558,000 after buying an additional 1,798 shares in the last quarter. Meeder Advisory Services Inc. grew its stake in shares of Vaxcyte by 2.9% during the 1st quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock valued at $484,000 after acquiring an additional 231 shares during the period. Finally, WCM Investment Management LLC bought a new position in shares of Vaxcyte during the 1st quarter valued at approximately $6,190,000. Institutional investors own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $57.28, for a total value of $572,800.00. Following the sale, the chief financial officer owned 104,395 shares in the company, valued at $5,979,745.60. The trade was a 8.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total transaction of $126,742.50. Following the completion of the sale, the chief operating officer owned 156,760 shares in the company, valued at approximately $8,830,290.80. The trade was a 1.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 91,396 shares of company stock worth $4,975,725. Insiders own 3.30% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Zacks Research lowered shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Vaxcyte presently has a consensus rating of “Hold” and a consensus price target of $86.00.

View Our Latest Stock Report on Vaxcyte

Vaxcyte Price Performance

Shares of PCVX opened at $54.08 on Friday. The firm has a market cap of $7.81 billion, a P/E ratio of -7.86 and a beta of 1.22. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00. The company has a 50 day simple moving average of $53.25 and a two-hundred day simple moving average of $54.89.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the firm earned ($1.04) EPS. On average, sell-side analysts anticipate that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

Vaxcyte Company Profile

(Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.